From: Cost of antipsychotic polypharmacy in the treatment of schizophrenia
Concurrent drug class with index drug | OLZ (N = 405) | RIS (N = 276) | QUE (N = 115) | p-value** (OLZ vs QUE) | p-value** (OLZ vs RIS) | p-value** (RIS vs QUE) |
---|---|---|---|---|---|---|
Total days on index drug post 1 year after initiation | 280 | 260 | 239 | 0.0028 | 0.0435 | 0.0557 |
First episode of continuously on index drug | 272 | 250 | 225 | 0.0023 | 0.0908 | 0.0162 |
Total concurrent days on other antipsychotics* | ||||||
on other atypicals | 36.1 | 49.4 | 110.6 | < 0.0001 | 0.0742 | 0.0001 |
on typicals | 105.1 | 79.3 | 69.4 | 0.0107 | 0.0119 | 0.4723 |
on all anti-psychotics | 136.6 | 120.3 | 160.2 | 0.1106 | 0.1378 | 0.0109 |
Percent of patients with >= 30 days of concurrent use | ||||||
on other atypicals | 18.5% | 25.4% | 52.2% | < 0.0001 | 0.0322 | < 0.0001 |
on typicals | 48.2% | 38.4% | 33.0% | 0.0041 | 0.0120 | 0.3171 |
on all anti-psychotics | 61.7% | 55.1% | 72.2% | 0.0396 | 0.0831 | 0.0017 |